PRIMARY MEMBRANOUS NEPHROPATHY
Clinical trials for PRIMARY MEMBRANOUS NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEMBRANOUS NEPHROPATHY trials appear
Sign up with your email to follow new studies for PRIMARY MEMBRANOUS NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise in battle against rare kidney disease
Disease control OngoingThis study tests a drug called zanubrutinib in people with primary membranous nephropathy (PMN), a kidney disease that causes protein leakage in urine. The goal is to see if zanubrutinib can reduce protein levels and lead to remission better than the current standard treatment, t…
Matched conditions: PRIMARY MEMBRANOUS NEPHROPATHY
Phase: PHASE2, PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 17, 2026 09:23 UTC
-
New drug zuberitamab takes on kidney disease in Head-to-Head trial
Disease control OngoingThis study tests a new medicine, zuberitamab, against a standard treatment (cyclosporine) in 135 adults with primary membranous nephropathy, a kidney condition that causes protein leakage. The goal is to see if zuberitamab can better reduce protein in urine over 76 weeks, while c…
Matched conditions: PRIMARY MEMBRANOUS NEPHROPATHY
Phase: PHASE2 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 09:16 UTC
-
New hope for kidney patients: drug may beat standard therapy
Disease control OngoingThis study tests a drug called obinutuzumab against a standard treatment (tacrolimus) in 142 people with primary membranous nephropathy, a kidney disease that lets protein leak into urine. The goal is to see if obinutuzumab can put the disease into complete remission by week 104.…
Matched conditions: PRIMARY MEMBRANOUS NEPHROPATHY
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 17, 2026 09:11 UTC
-
Kidney treatment showdown: new drug vs. standard care in REMIT trial
Disease control TerminatedThis study aimed to compare a newer drug, obinutuzumab, with a standard combination of steroids and cyclophosphamide for treating primary membranous nephropathy, a kidney condition that causes protein leakage. The plan was to enroll 224 adults worldwide and measure success based …
Matched conditions: PRIMARY MEMBRANOUS NEPHROPATHY
Phase: PHASE3 • Sponsor: The University of Queensland • Aim: Disease control
Last updated May 04, 2026 16:21 UTC